Non-genomic regulation of vascular cell function and growth by estrogen

Molecular and Cellular Endocrinology

Volumn 308, Issue 1-2, 2009, Pages 9-16

  Meyer, Matthias R ^a   Haas, Elvira ^a   Prossnitz, Eric R ^b   Barton, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Endothelial cell; Estradiol; Estrogen receptor; Genomic signaling; GPER; GPR30; Non genomic signaling; Plasma membrane; Vascular smooth muscle cell

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; NITRIC OXIDE; RALOXIFENE; TAMOXIFEN;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; BLOOD VESSEL WALL; BREAST CANCER; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOSKELETON; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; ESTROGEN BINDING; GENE EXPRESSION REGULATION; GROWTH REGULATION; HUMAN; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ACTINS; ANIMALS; CELL SURVIVAL; CYTOSKELETON; ENDOTHELIAL CELLS; ESTROGENS; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 67449152265     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.03.009     Document Type: Review

References (100)

1. Acconcia F., Ascenzi P., Bocedi A., Spisni E., Tomasi V., Trentalance A., Visca P., and Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol. Biol. Cell 16 (2005) 231-237
2. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S., and Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 (2007) 1859-1866
3. Aronica S.M., Kraus W.L., and Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8517-8521
4. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., McNabb M.A., and Wenger N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355 (2006) 125-137
5. Barton M. Postmenopausal oestrogen replacement therapy and atherosclerosis: can current compounds provide cardiovascular protection?. Exp. Opin. Investig. Drugs 10 (2001) 789-809
6. Barton M., and Haudenschild C.C. Endothelium and atherogenesis: endothelial therapy revisited. J. Cardiovasc. Pharmacol. 38 Suppl. 2 (2001) S23-S25
7. Barton, M., Kockx, M.M., 2002. Estrogen and apoptosis in atherosclerosis. Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000. In: Samioe, G., Skouby, S. (Eds.), Midlife Health-Current Concepts and Challenges for the Future. Elsevier International Congress Series, Amsterdam, pp. 81-93.
8. Barton M., Meyer M.R., and Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1669-1672
9. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19 (2005) 833-842
10. Boonyaratanakornkit V., and Edwards D.P. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin. Reprod. Med. 25 (2007) 139-153
11. Bouallegue A., Daou G.B., and Srivastava A.K. Nitric oxide attenuates endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 in vascular smooth muscle cells by a cGMP-dependent pathway. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H2072-2079
12. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P., German Z., Sherman T.S., Mendelsohn M.E., Anderson R.G., and Shaul P.W. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 87 (2000) E44-52
13. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., and Shaul P.W. ERbeta has nongenomic action in caveolae. Mol. Endocrinol. 16 (2002) 938-946
14. Chen D.B., Bird I.M., Zheng J., and Magness R.R. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 145 (2004) 113-125
15. Cheng, B., Song, J., Zou, Y., Wang, Q., Lei, Y., Zhu, C., Hu, C., 2008. Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities. Int. J. Cardiol., published online.
16. Cheskis B.J., Greger J.G., Nagpal S., and Freedman L.P. Signaling by estrogens. J. Cell Physiol. 213 (2007) 610-617
17. Cheskis B.J., Greger J., Cooch N., McNally C., McLarney S., Lam H.S., Rutledge S., Mekonnen B., Hauze D., Nagpal S., and Freedman L.P. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73 (2008) 901-905
18. Collins P., Mosca L., Geiger M.J., Grady D., Kornitzer M., Amewou-Atisso M.G., Effron M.B., Dowsett S.A., Barrett-Connor E., and Wenger N.K. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial. Results of Subgroup Analyses by Age and Other Factors. Circulation 119 (2009) 922-930
19. Dubey R.K., Jackson E.K., Gillespie D.G., Zacharia L.C., Imthurn B., and Keller P.J. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 964-972
20. Faul C., Asanuma K., Yanagida-Asanuma E., Kim K., and Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17 (2007) 428-437
21. Feletou M., and Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1215-1225
22. Figtree G.A., McDonald D., Watkins H., and Channon K.M. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 107 (2003) 120-126
23. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000) 1649-1660
24. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16 (2002) 70-84
25. Filardo E.J., Graeber C.T., Quinn J.A., Resnick M.B., Giri D., DeLellis R.A., Steinhoff M.M., and Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12 (2006) 6359-6366
26. Filardo E.J., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., and Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148 (2007) 3236-3245
27. Force T., and Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension 31 (1998) 152-161
28. Fu X.D., and Simoncini T. Non-genomic sex steroid actions in the vascular system. Semin. Reprod. Med. 25 (2007) 178-186
29. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83 (1989) 1774-1777
30. Geraldes P., Sirois M.G., Bernatchez P.N., and Tanguay J.F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1585-1590
31. Geraldes P., Sirois M.G., and Tanguay J.F. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ. Res. 93 (2003) 399-405
32. Giretti M.S., and Simoncini T. Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids 73 (2008) 895-900
33. Grasselli A., Nanni S., Colussi C., Aiello A., Benvenuti V., Ragone G., Moretti F., Sacchi A., Bacchetti S., Gaetano C., Capogrossi M.C., Pontecorvi A., and Farsetti A. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ. Res. 103 (2008) 34-42
34. Greger J.G., Fursov N., Cooch N., McLarney S., Freedman L.P., Edwards D.P., and Cheskis B.J. Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol. Cell Biol. 27 (2007) 1904-1913
35. Haas E., Meyer M.R., Schurr U., Bhattacharya I., Minotti R., Nguyen H.H., Heigl A., Lachat M., Genoni M., and Barton M. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 49 (2007) 1358-1363
36. Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., Resta T.C., Prossnitz E.R., and Barton M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 104 (2009) 288-291
37. Haynes M.P., Sinha D., Russell K.S., Collinge M., Fulton D., Morales-Ruiz M., Sessa W.C., and Bender J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res. 87 (2000) 677-682
38. Haynes M.P., Li L., Russell K.S., and Bender J.R. Rapid vascular cell responses to estrogen and membrane receptors. Vascul. Pharmacol. 38 (2002) 99-108
39. Haynes M.P., Li L., Sinha D., Russell K.S., Hisamoto K., Baron R., Collinge M., Sessa W.C., and Bender J.R. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J. Biol. Chem. 278 (2003) 2118-2123
40. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
41. Kanda N., and Watanabe S. 17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. J. Invest. Dermatol. 121 (2003) 1500-1509
42. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Metzger D., and Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 (1995) 1491-1494
43. Katzenellenbogen B.S., Montano M.M., Ediger T.R., Sun J., Ekena K., Lazennec G., Martini P.G., McInerney E.M., Delage-Mourroux R., Weis K., and Katzenellenbogen J.A. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res. 55 (2000) 163-193 discussion 194-165
44. Kishi Y., and Numano F. A study of the mechanism of estrogen as an antiatherosclerotic: the inhibitory effect of estrogen on A23187-induced contraction of the aortic wall. Mech. Ageing Dev. 18 (1982) 115-123
45. Kleuser B., Malek D., Gust R., Pertz H.H., and Potteck H. 17-{beta}-estradiol inhibits transforming growth factor-{beta} signalling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein coupled receptor 30. Mol. Pharmacol. 74 (2008) 1533-1543
46. Kockx M.M., and Herman A.G. Apoptosis in atherosclerosis: beneficial or detrimental?. Cardiovasc. Res. 45 (2000) 736-746
47. Kumar P., Wu Q., Chambliss K.L., Yuhanna I.S., Mumby S.M., Mineo C., Tall G.G., and Shaul P.W. Direct interactions with G alpha i and G betagamma mediate nongenomic signaling by estrogen receptor alpha. Mol. Endocrinol. 21 (2007) 1370-1380
48. Lafferty A.R., Torpy D.J., Stowasser M., Taymans S.E., Lin J.P., Huggard P., Gordon R.D., and Stratakis C.A. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J. Med. Genet. 37 (2000) 831-835
49. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 19 (2005) 1951-1959
50. Li L., Haynes M.P., and Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4807-4812
51. Li L., Hisamoto K., Kim K.H., Haynes M.P., Bauer P.M., Sanjay A., Collinge M., Baron R., Sessa W.C., and Bender J.R. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16468-16473
52. Liu W.L., Guo X., and Guo Z.G. Estrogen prevents bovine aortic endothelial cells from TNF-alpha-induced apoptosis via opposing effects on p38 and p44/42 CCDPK. Acta Pharmacol. Sin. 23 (2002) 213-218
53. Lu Q., Pallas D.C., Surks H.K., Baur W.E., Mendelsohn M.E., and Karas R.H. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17126-17131
54. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., and Ando S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 279 (2004) 27008-27016
55. Mårtensson U.E., Salehi S.A., Windahl S., Gomez M.F., Sward K., Daszkiewicz-Nilsson J., Wendt A., Andersson N., Hellstrand P., Grande P.O., Owman C., Rosen C.J., Adamo M.L., Lundquist I., Rorsman P., Nilsson B.O., Ohlsson C., Olde B., and Leeb-Lundberg L.M. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150 (2009) 687-698
56. Matthews J., and Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interven. 3 (2003) 281-292
57. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340 (1999) 1801-1811
58. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
59. Mercier I., Mader S., and Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc. Res. 59 (2003) 883-892
60. Meyer M.R., Haas E., and Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 47 (2006) 1019-1026
61. Meyer M.R., Haas E., and Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend. Med. 5 Suppl. A (2008) S19-S33
62. Migliaccio A., Castoria G., Di Domenico M., De Falco A., Bilancio A., and Auricchio F. Src is an initial target of sex steroid hormone action. Ann. N. Y. Acad. Sci. 963 (2002) 185-190
63. Miller V.M., and Duckles S.P. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60 (2008) 210-241
64. Morey A.K., Pedram A., Razandi M., Prins B.A., Hu R.M., Biesiada E., and Levin E.R. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 138 (1997) 3330-3339
65. Mori-Abe A., Tsutsumi S., Takahashi K., Toya M., Yoshida M., Du B., Kawagoe J., Nakahara K., Takahashi T., Ohmichi M., and Kurachi H. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 178 (2003) 417-426
66. Moriarty K., Kim K.H., and Bender J.R. Mini review: estrogen receptor-mediated rapid signaling. Endocrinology 147 (2006) 5557-5563
67. Mügge A., Riedel M., Barton M., Kuhn M., and Lichtlen P.R. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc. Res. 27 (1993) 1939-1942
68. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., and Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 81 (2001) 1535-1565
69. O'Lone R., Frith M.C., Karlsson E.K., and Hansen U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 18 (2004) 1859-1875
70. O'Lone R., Knorr K., Jaffe I.Z., Schaffer M.E., Martini P.G., Karas R.H., Bienkowska J., Mendelsohn M.E., and Hansen U. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol. Endocrinol. 21 (2007) 1281-1296
71. Okamoto T., Schlegel A., Scherer P.E., and Lisanti M.P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273 (1998) 5419-5422
72. Pedram A., Razandi M., and Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. 20 (2006) 1996-2009
73. Pedram A., Razandi M., Sainson R.C., Kim J.K., Hughes C.C., and Levin E.R. A conserved mechanism for steroid receptor translocation to the plasma membrane. J. Biol. Chem. 282 (2007) 22278-22288
74. Pietras R.J., and Szego C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265 (1977) 69-72
75. Prossnitz E.R., Arterburn J.B., Smith H.O., Oprea T.I., Sklar L.A., and Hathaway H.J. Estrogen Signaling through the Transmembrane G Protein-Coupled Receptor GPR30. Annu. Rev. Physiol. 70 (2008) 165-190
76. Razandi M., Pedram A., Greene G.L., and Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13 (1999) 307-319
77. Razandi M., Pedram A., and Levin E.R. Estrogen signals to the preservation of endothelial cell form and function. J. Biol. Chem. 275 (2000) 38540-38546
78. Razandi M., Oh P., Pedram A., Schnitzer J., and Levin E.R. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol. 16 (2002) 100-115
79. Razandi M., Pedram A., Merchenthaler I., Greene G.L., and Levin E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 18 (2004) 2854-2865
80. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
81. Revankar C.M., Mitchell H.D., Field A.S., Burai R., Corona C., Ramesh C., Sklar L.A., Arterburn J.B., and Prossnitz E.R. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem. Biol. 2 (2007) 536-544
82. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
83. Russell K.S., Haynes M.P., Sinha D., Clerisme E., and Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5930-5935
84. Schubert V., and Dotti C.G. Transmitting on actin: synaptic control of dendritic architecture. J. Cell Sci. 120 (2007) 205-212
85. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
86. Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., and Genazzani A.R. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69 (2004) 537-542
87. Simoncini T., Scorticati C., Mannella P., Fadiel A., Giretti M.S., Fu X.D., Baldacci C., Garibaldi S., Caruso A., Fornari L., Naftolin F., and Genazzani A.R. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol. Endocrinol. 20 (2006) 1756-1771
88. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., and Prossnitz E.R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 196 (2007) 386.e1-386.e9 (discussion: 386.e9-389.e11)
89. Somjen D., Kohen F., Gayer B., Sharon O., Baz M., Limor R., Kulik T., Knoll E., and Stern N. Role of putative membrane receptors in the effects of estradiol on human vascular cell growth. Am. J. Hypertens. 17 (2004) 462-469
90. Song R.X., Barnes C.J., Zhang Z., Bao Y., Kumar R., and Santen R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2076-2081
91. Szego C.M., and Davis J.S. Inhibition of estrogen-induced cyclic AMP elevation in rat uterus. II: By glucocorticoids. Life Sci. 8 (1969) 1109-1116
92. Taguchi Y., Koslowski M., and Bodenner D.L. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl. Recept. 2 (2004) 5
93. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
94. Traupe T., Stettler C.D., Li H., Haas E., Bhattacharya I., Minotti R., and Barton M. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 49 (2007) 1364-1370
95. Ullrich N.D., Krust A., Collins P., and MacLeod K.T. Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H2421-2427
96. Vadlamudi R.K., and Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl. Recept. Signal 5 (2007) e004
97. Vivacqua A., Bonofiglio D., Albanito L., Madeo A., Rago V., Carpino A., Musti A.M., Picard D., Ando S., and Maggiolini M. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol. Pharmacol. 70 (2006) 1414-1423
98. Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Ando S., and Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 20 (2006) 631-646
99. Wang C., Dehghani B., Magrisso I.J., Rick E.A., Bonhomme E., Cody D.B., Elenich L.A., Subramanian S., Murphy S.J., Kelly M.J., Rosenbaum J.S., Vandenbark A.A., and Offner H. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 22 (2008) 636-648
100. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331